IB 367.
D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D023181:Antimicrobial Cationic Peptides; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D015507:Drugs, Investigational / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005658:Fungi / Q000187:drug effects; D006801:Humans; D009059:Mouth Diseases / Q000188:drug therapy / Q000382:microbiology; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology; D010455:Peptides; D011506:Proteins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000935:Antifungal Agents; D023181:Antimicrobial Cationic Peptides; D015507:Drugs, Investigational; D010455:Peptides; D011506:Proteins; C119872:antimicrobial peptide IB-367